Valuation : NEOVACS SA

Market Cap 4.09K 4.75K 3.85K 3.51K 6.57K 450K 6.59K 45.6K 17.63K 230K 17.86K 17.47K 733K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -234K -189K -173K -323K -22.1M -324K -2.24M -866K -11.32M -878K -858K -36.05M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 68.39K
-1.16%-2.77%-1.68%+13.85% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
-0.96%-2.31%+15.75%+45.41% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.54%-1.30%+12.02%+31.14% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.96%+0.48%+73.69%+109.93% 30.55B
Weighted average by Cap. -0.95%+0.05%+89.18%+128.66%

Financials

2023 2024
Net sales 533K 620K 502K 458K 857K 58.66M 859K 5.95M 2.3M 30.04M 2.33M 2.28M 95.68M 434K 505K 408K 373K 697K 47.72M 699K 4.84M 1.87M 24.44M 1.89M 1.85M 77.84M
Net income -8.74M -10.17M -8.22M -7.51M -14.04M -962M -14.09M -97.5M -37.69M -492M -38.18M -37.35M -1.57B -32.91M -38.27M -30.96M -28.26M -52.85M -3.62B -53.02M -367M -142M -1.85B -144M -141M -5.9B
Net Debt -237K -275K -222K -203K -380K -26.01M -381K -2.64M -1.02M -13.32M -1.03M -1.01M -42.42M -205K -238K -193K -176K -329K -22.55M -330K -2.29M -884K -11.55M -896K -876K -36.79M
Logo NEOVACS SA
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!